MEDEZE Reinforces Its Leadership in Stem Cell Banking with Comprehensive Certifications

MEDEZE Group Public Company Limited ("MEDEZE"), a leading stem cell banking provider accredited to international standards and the first and only company in Thailand to achieve the country's Cell Banking Standard certification, continues to strengthen its leadership in stem cell banking and regenerative medicine. The Company has established a comprehensive infrastructure that meets both national and international standards, encompassing the Pharmaceutical Manufacturing License (Por.Yor.2), Cell Banking certification issued by Thailand's Ministry of Public Health, AABB and ISO certifications, compliance with the regulatory requirements of the Stock Exchange of Thailand, and participation in the Advanced Therapy Medicinal Products (ATMPs) Regulatory Sandbox, supporting the advancement of Thailand's advanced medical products industry.

Dr. Veerapol Khemarangsan, Chief Executive Officer of MEDEZE Group Public Company Limited, stated that the Company remains committed to strengthening confidence among the public, investors, and the medical community through the development of a comprehensive infrastructure for stem cell banking and Advanced Therapy Medicinal Products (ATMPs) under standards recognized both domestically and internationally.

Currently, MEDEZE has obtained the Pharmaceutical Manufacturing License (Por.Yor.2) issued by the Thai Food and Drug Administration (Thai FDA), authorizing the manufacture of cell therapy products for clinical research. The Company is also the first organization in Thailand to be certified under the national Cell Banking Standard, accredited by the Department of Medical Sciences in accordance with the Ministry of Public Health's official regulations published in the Royal Gazette and developed in alignment with international standards. In addition, MEDEZE has earned internationally recognized AABB and ISO certifications while continuously expanding its research capabilities, strengthening collaborations with leading medical institutions, and advancing innovations in regenerative medicine.

Furthermore, MEDEZE is among the key organizations driving the development of Thailand's ATMP industry through its participation in the ATMPs Sandbox, a collaborative initiative involving government agencies, medical institutions, and the private sector. The program aims to support the development and commercialization of advanced therapy medicinal products in accordance with international standards while fostering a comprehensive regenerative medicine ecosystem—from cell collection, research, development, and manufacturing to clinical applications—ultimately expanding Thai patients' access to next-generation medical innovations.

"MEDEZE is committed to building our organization upon verifiable standards covering regulatory compliance, quality, and internationally recognized certifications. These include our Pharmaceutical Manufacturing License (Por.Yor.2), an AABB- and ISO-accredited Cell Bank, and participation in the Advanced Therapy Medicinal Products (ATMPs) Sandbox. Together, these achievements reflect our capability to contribute meaningfully to the advancement of Thailand's advanced medical products industry."

Dr. Veerapol added:

"We see ourselves as more than a stem cell banking service provider. Our vision is to establish a fully integrated healthcare infrastructure for the future—covering cell collection, research, and manufacturing under internationally recognized standards while supporting the development of Advanced Therapy Medicinal Products (ATMPs). Through these efforts, we aim to strengthen Thailand's position as a regional hub for regenerative medicine and medical innovation."

For individuals seeking a trusted stem cell banking provider, MEDEZE offers internationally recognized quality standards, including ISO 9001:2015 certification and AABB accreditation, supported by proven technologies such as the AXP AutoXpress® Platform and advanced cryopreservation systems. These technologies ensure precision and safety throughout every stage of cell processing and storage, covering umbilical cord blood, umbilical cord tissue, adipose tissue, hair follicles, and NK cells, providing comprehensive solutions for long-term health and future regenerative medicine applications.

For more information, please visit: https://www.medezegroup.com/th/